

# Simon Ekman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6388032/publications.pdf>

Version: 2024-02-01

34  
papers

712  
citations

686830

13  
h-index

580395

25  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1104  
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition of Synchronous Oligometastatic Non-“Small Cell Lung Cancer” A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	0.5	189
2	Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression. <i>Lung Cancer</i> , 2018, 124, 45-52.	0.9	53
3	Effect of corticosteroids on the outcome of patients with advanced non-“small cell lung cancer treated with immune-checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 145, 245-254.	1.3	52
4	Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. <i>PLoS ONE</i> , 2017, 12, e0187246.	1.1	51
5	Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). <i>Lung Cancer</i> , 2020, 143, 27-35.	0.9	42
6	Early-Stage NSCLC: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019, 14, 968-978.	0.5	35
7	RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer. <i>Genes and Development</i> , 2017, 31, 2099-2112.	2.7	32
8	Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer – Review article. <i>Surgical Oncology</i> , 2017, 26, 290-295.	0.8	27
9	Oncogene-addicted non-small cell lung cancer and immunotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1547-S1555.	0.6	25
10	c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 133, 69-74.	0.9	22
11	miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. <i>Biochemical and Biophysical Research Communications</i> , 2019, 511, 260-265.	1.0	19
12	HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of $\beta$ -catenin-FGF18 pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 91.	3.5	18
13	I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. <i>Future Oncology</i> , 2019, 15, 1551-1563.	1.1	16
14	Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR. <i>Cancers</i> , 2021, 13, 922.	1.7	15
15	Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial. <i>Lung Cancer</i> , 2018, 122, 180-186.	0.9	14
16	An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-“small-cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 24-34.	1.3	14
17	Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a “Real-Life”™ Setting. <i>Cancers</i> , 2020, 12, 3707.	1.7	12
18	Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy. <i>Cancers</i> , 2021, 13, 1562.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients. <i>Biosensors and Bioelectronics</i> , 2021, 193, 113568.	5.3	10
20	Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer. <i>Acta OncolÅ³gica</i> , 2018, 57, 231-238.	0.8	9
21	Multiplex immune protein profiling of fineâ€needle aspirates from patients with nonâ€smallâ€cell lung cancer reveals signatures associated with PDâ€1 expression and tumor stage. <i>Molecular Oncology</i> , 2021, 15, 2941-2957.	2.1	8
22	How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2020, 9, 2535-2544.	1.3	7
23	Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100165.	0.6	6
24	Complications following novel therapies for nonâ€small cell lung cancer. <i>Journal of Internal Medicine</i> , 2022, 291, 732-754.	2.7	6
25	Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3430.	1.7	4
26	ALK-Brain Prognostic Indexâ€”Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases. <i>Cancers</i> , 2020, 12, 1804.	1.7	3
27	Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition. <i>Clinical Lung Cancer</i> , 2020, 21, e544-e546.	1.1	3
28	High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC. <i>Cancers</i> , 2021, 13, 3151.	1.7	2
29	Intracranial effect of osimertinib in relapsed <i>EGFR</i>-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. <i>Acta OncolÅ³gica</i> , 2021, 60, 1565-1571.	0.8	2
30	Rapid drop in blood platelet count and increase in creatinine in non-small cell lung cancer (NSCLC) patients treated with osimertinib.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21026-e21026.	0.8	2
31	Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005â€2015): SCAN-LEAF study. <i>Future Oncology</i> , 2021, , .	1.1	2
32	Programmed Cell Death Ligand 1 Expression in Resected Nonâ€Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 22, e555-e562.	1.1	1
33	Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies. <i>Life</i> , 2022, 12, 880.	1.1	1
34	Treatment beyond RECIST-defined progression in relapsed EGFR-mutated non-small cell lung cancer (NSCLC) patients treated with 2nd line osimertinib.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20544-e20544.	0.8	0